Spots Global Cancer Trial Database for A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma
Official Title: A Phase II Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-naive IDH1 Mutated WHO Grade II Glioma
Study ID: NCT04458272
Conditions
Interventions
Study Description
Brief Summary: This Phase 2 study is conducted to assess the efficacy and safety of DS-1001b in patients with chemotherapy- and radiotherapy-naive IDH1 mutated WHO grade II glioma.
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Nagoya University Hospital, Nagoya, Aichi, Japan
Kitasato University Hospital, Sagamihara, Kanagawa, Japan
Tohoku University Hospital, Sendai, Miyagi, Japan
Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
Hiroshima University Hospital, Hiroshima, , Japan
Kumamoto University Hospital, Kumamoto, , Japan
Kyoto University Hospital, Kyoto, , Japan
National Hospital Organization Osaka National Hospital, Osaka, , Japan
Kyorin University Hospital, Tokyo, , Japan
National Cancer Center Hospital, Tokyo, , Japan
Tokyo Women's Medical University Hospital, Tokyo, , Japan
Contact Details
Name: Clinical Study Leader
Affiliation: Daiichi Sankyo
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
